European Companies Search Engine
EU funding (€3,811,581): Development of Selective Carbohydrate Immunomodulators Targeting C-type Lectin Receptors on Antigen Presenting Cells Hor1 Jan 2015 EU Research and Innovation programme "Horizon"
Overview
Text
Development of Selective Carbohydrate Immunomodulators Targeting C-type Lectin Receptors on Antigen Presenting Cells
IMMUNOSHAPE aims at training a new generation of scientists that will be capable of combining state of the art synthesis and screening technology to develop new lead structures for highly selective glycan based multivalent immunotherapeutics for the treatment of cancer, autoimmune diseases and allergy. To this end, we have set up a training program in a unique academic-industrial environment that will educate young researchers in scientific and practical biomedical glycoscience with the final aim to produce new talent and innovation in the field and improve their career perspectives in both academic and non-academic sectors. The unique combination of 10 academic groups with expertise in automated solid-phase carbohydrate synthesis, microarray based highthroughput screening technology, tumour immunology, structural glycobiology, multivalent systems and medicinal chemistry along with 4 industrial partners active in nanomedicine, immunotherapy, medicinal device development and the fabrication of scientific instrumentation will provide a multidisciplinary and multisectorial training to 15 ESRs in biomedical glycoscience and its industrial applications.
Funded Companies:
| Company name | Funding amount |
| Glaxosmithkline Vaccines Srl | ? |
| Agencia Estatal Consejo Superior de Investigaciones Cientificas | €247,873 |
| Asociacion Centro de Investigacion CRL en Biomateriales- Cic biomaGUNE | €495,746 |
| DC4U | €255,374 |
| DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG | €249,216 |
| Glycodiag | €262,876 |
| GLYCOUNIVERSE GmbH & Co. KGaA | €249,216 |
| MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN e. V. | €249,216 |
| Midatech Pharma Espana SL | €247,873 |
| STICHTING AMSTERDAM UMC | €255,374 |
| STICHTING VU | €0.00 |
| STIFTUNG TIERAERZTLICHE HOCHSCHULE HANNOVER | €249,216 |
| The University of Manchester | €273,288 |
| Universita Degli Studi Di Milano | €258,061 |
| Universite Grenoble Alpes | €262,876 |
| UNIVERSITEIT LEIDEN | €255,374 |
Source: https://cordis.europa.eu/project/id/642870
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Glaxosmithkline Vaccines Srl, Siena, Italy.
The visualizations for "Glaxosmithkline Vaccines Srl - EU funding (€3,811,581): Development of Selective Carbohydrate Immunomodulators Targeting C-type Lectin Receptors on Antigen Presenting Cells"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
